ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 240 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2023. The put-call ratio across all filers is 1.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $509,795 | +2.3% | 14,300 | +32.4% | 0.01% | 0.0% |
| Q2 2023 | $498,204 | +25.5% | 10,800 | +9.1% | 0.01% | +25.0% |
| Q1 2023 | $396,990 | +53.0% | 9,900 | +76.8% | 0.00% | +33.3% |
| Q4 2022 | $259,448 | +2.7% | 5,600 | -8.2% | 0.00% | 0.0% |
| Q3 2022 | $252,601 | -66.9% | 6,100 | -41.9% | 0.00% | -57.1% |
| Q1 2022 | $763,000 | -34.7% | 10,500 | -24.5% | 0.01% | -12.5% |
| Q4 2021 | $1,169,000 | +5.4% | 13,900 | +13.0% | 0.01% | -27.3% |
| Q3 2021 | $1,109,000 | +14.0% | 12,300 | +20.6% | 0.01% | +10.0% |
| Q2 2021 | $973,000 | -17.8% | 10,200 | -1.9% | 0.01% | -16.7% |
| Q1 2021 | $1,184,000 | -0.5% | 10,400 | +20.9% | 0.01% | 0.0% |
| Q4 2020 | $1,190,000 | +281.4% | 8,600 | +126.3% | 0.01% | +200.0% |
| Q3 2020 | $312,000 | +42.5% | 3,800 | +35.7% | 0.00% | +33.3% |
| Q2 2020 | $219,000 | – | 2,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 213,887 | $29,608,000 | 2.19% |
| Rock Springs Capital Management LP | 566,500 | $78,421,000 | 1.66% |
| FEDERATED HERMES, INC. | 4,280,528 | $592,554,000 | 1.21% |
| AtonRa Partners | 17,646 | $2,443,000 | 1.20% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 218,390 | $30,232,000 | 1.05% |
| EMERALD ADVISERS, LLC | 226,875 | $31,406,000 | 1.04% |
| Atika Capital Management LLC | 89,000 | $12,319,000 | 0.96% |
| Capital Impact Advisors, LLC | 25,582 | $3,541,000 | 0.87% |
| JGP Global Gestao de Recursos Ltda. | 1,586 | $220,000 | 0.83% |
| CAPITAL INTERNATIONAL LTD /CA/ | 79,742 | $11,039,000 | 0.64% |